COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer (SABRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00082277
Recruitment Status : Completed
First Posted : May 6, 2004
Last Update Posted : January 26, 2011
Information provided by:

Brief Summary:
The purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles. This trial is conducted to investigate the effects of risedronate on BMD and on bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone-receptor-positive early breast cancer and who are high or moderate risk of fragility fracture. It is also conducted to determine the effects of anastrozole on bone mineral density (BMD) and on bone metabolism in women at low risk of fragility fracture.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Anastrozole Drug: Risedronate Sodium Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 237 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicentre Phase III/IV Study, of the Effects of Risedronate Sodium (ACTONEL™, 35mg/Week, Oral) on Bone, in Postmenopausal Women, With Hormone-receptor-positive Early Breast Cancer, Treated With Anastrozole (ARIMIDEX™, 1mg/Day Oral) With Risk of Fragility Fracture (High-risk Fragility Fracture-open-label, Non-comparative Stratum; Moderate-risk of Fragility Fracture-randomised, Double-blind Stratum; Low-risk of Fragility Fracture - Open-label, Non-comparative Stratum)Abbreviated
Study Start Date : April 2004
Actual Primary Completion Date : October 2007
Actual Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
Drug: Anastrozole
1mg/Day Oral
Other Names:
  • ZD1033

Drug: Risedronate Sodium
35mg/week, oral
Other Name: ACTONEL™

Experimental: 2
Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
Drug: Anastrozole
1mg/Day Oral
Other Names:
  • ZD1033

Drug: Risedronate Sodium
35mg/week, oral
Other Name: ACTONEL™

Experimental: 3
Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
Drug: Anastrozole
1mg/Day Oral
Other Names:
  • ZD1033

Drug: Risedronate Sodium
35mg/week, oral
Other Name: ACTONEL™

Primary Outcome Measures :
  1. The change from baseline in lumbar spine (L1-L4) bone mineral density (BMD) [ Time Frame: Assessed at 12 months ]

Secondary Outcome Measures :
  1. Change from baseline in total hip BMD [ Time Frame: Assessed at 12 and 24 months ]
  2. Change from baseline in lumbar spine (L1-L4) BMD [ Time Frame: Assessed at 24 months ]
  3. Change from baseline in bone formation markers [ Time Frame: Assessed at 6 and12 months ]
  4. Change from baseline in bone resorption and formation markers [ Time Frame: Assessed at 6 and 12 months ]
  5. Change from baseline in LDL-cholesterol [ Time Frame: Assessed at 12 months ]
  6. Change from baseline in LDL-cholesterol, HDL-cholesterol, total cholesterol, and serum triglycerides [ Time Frame: Assessed at 3, 6 and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women defined as Postmenopausal
  • Histologically proven operable invasive breast cancer
  • Hormone-receptor-positive breast cancer

Exclusion Criteria:

  • Clinical evidence of metastatic disease
  • Bilateral hip fractures or bilateral hip prosthesis
  • Receiving or received in last 12 months hormonal therapy for breast cancer, bisphosphonate therapy, oestrogens
  • Malabsorption syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00082277

Layout table for location information
United States, California
Research Site
Palm Springs, California, United States
United States, Florida
Research Site
Jacksonville, Florida, United States
United States, Louisiana
Research Site
New Orleans, Louisiana, United States
United States, New York
Research Site
New York, New York, United States
United States, North Carolina
Research Site
Raleigh, North Carolina, United States
United States, Ohio
Research Site
Cleveland, Ohio, United States
United States, Pennsylvania
Research Site
Pittsburgh, Pennsylvania, United States
United States, Texas
Research Site
Houston, Texas, United States
Research Site
Burnaby, Canada
Research Site
Edmonton, Canada
Research Site
Montreal, Canada
Research Site
Quebec City, Canada
Research Site
Vancouver, Canada
Research Site
Bordeaux, France
Research Site
Caen, France
Research Site
Lyon, France
Research Site
Saint-Cloud, France
Research Site
Saint-Herblain, France
Research Site
Athens, Greece
Research Site
Iraklion, Greece
Research Site
Den Haag, Netherlands
Research Site
Goes, Netherlands
Research Site
Ijssel, Netherlands
Research Site
Nijmegen, Netherlands
South Africa
Research Site
Bloemfontain, South Africa
Research Site
Cape Town, South Africa
Research Site
Tygerberg, South Africa
Research Site
Pamplona, Spain
Research Site
Pontevedra, Spain
Research Site
Sevilla, Spain
Research Site
Valencia, Spain
United Kingdom
Research Site
Belfast, United Kingdom
Research Site
Bolton, United Kingdom
Research Site
Dundee, United Kingdom
Research Site
Luton, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Study Director: AstraZeneca Arimidex Medical Science Director, MD AstraZeneca
Layout table for additonal information
Responsible Party: Francisco Sapunar, MD - Arimidex Medical Science Director, AstraZeneca Identifier: NCT00082277    
Other Study ID Numbers: D5392C00050
First Posted: May 6, 2004    Key Record Dates
Last Update Posted: January 26, 2011
Last Verified: January 2011
Keywords provided by AstraZeneca:
hormone-receptor positive, breast cancer
risk of fracture
bone loss
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Risedronic Acid
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Bone Density Conservation Agents